Prostate News Archive
24-Oct-2007
Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer (PR Newswire via Yahoo! Finance)
Dendreon Corporation today announced that the Company has completed enrollment of over 500 patients in the Phase 3 IMPACT clinical trial of PROVENGE , the Company's investigational active cellular immunotherapy for the treatment of advanced prostate cancer. Yale Cancer Center Sponsors Study of Phenoxodiol for Prostate Cancer (Marketwire via Yahoo! Finance)
Yale researchers have begun recruiting 60 men for a clinical trial investigating an experimental new drug, oral phenoxodiol, as a potential first line therapy for prostate cancer. The study is funded by Yale Cancer Center. Selected Studies: Prostate Cancer (New York Times)
Notable research studies enrolling patients. Decision-Making About PSA Testing And Prostate Biopsies: A Qualitative Study Embedded In A Primary Care Randomized Trial (Medical News Today)
UroToday.com- Most men surveyed in a study in the UK felt that PSA testing and prostate biopsy were acceptable, according to an online report by Dr. Avery and colleagues that appears in European Urology. The study investigated men's views of PSA testing and biopsy and sought to explore how beliefs influence health behavior. [click link for full article]
Back to Prostate News Archive
